

Global Blood Cancer Drugs Market Trends, Strategies, And Opportunities In The Blood Cancer Drugs Market 2021-2030

The Business Research Company's Blood Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery

LONDON, GREATER LONDON, UK, August 19, 2021 /EINPresswire.com/ --According to the new market research report 'Blood Cancer Drugs Global Market Report 2021 - By Blood Cancer Type (Leukemia, Lymphoma,



Myeloma), By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), By Treatment Approaches (Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic), COVID-19 Impact And Recovery' published by The Business Research Company, the blood cancer drugs market is expected to grow from \$20.66 billion in 2020 to \$21.6 billion in 2021 at a compound annual growth rate (CAGR) of 4.5%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach \$28.7 billion in 2025 at a CAGR of 7.4%. The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe.

Request For A Sample For The Global Blood Cancer Drugs Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp

The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukaemia, lymphoma, and myeloma. The blood cancer drugs include Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin) and others.

Trends In The Global Blood Cancer Drugs Market

Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. Al is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For instance, Johnson and Johnson entered into an agreement with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs.

Global Blood Cancer Drugs Market Segments:

The global blood cancer drugs market is further segmented based on blood cancer type, drugs, treatment approaches and geography.

By Blood Cancer Type: Leukemia, Lymphoma, Myeloma

By Drugs: MabThera / Rituxan (rituximab), Gleevec/Glivec (Imatinib), REVLIMID® (lenalidomide), VELCADE® (bortezomib), TASIGNA® (nilotinib), POMALYST® (pomalidomide), Vidaza (Azacitidine), KYPROLIS® (carfilzomib), ADCETRIS® (brentuximab vedotin), Others

By Treatment Approaches: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic

By Geography: The global blood cancer drugs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Blood Cancer Drugs Market At: https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Blood Cancer Drugs Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides blood cancer drugs global market overviews, analyzes and forecasts market size and growth for the global blood cancer drugs global market, blood cancer drugs global market share, blood cancer drugs market players, blood cancer drugs market segments and geographies, blood cancer drugs market's leading competitors' revenues, profiles and market shares. The blood cancer drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors' approaches.

Read Blood Cancer Drugs Global Market Report 2021 from The Business Research Company for information on the following:

Data Segmentations: Market Size, Global, By Region And By Country; Historic And Forecast Size, And Growth Rates For The World, 7 Regions And 12 Countries

Blood Cancer Drugs Market Organizations Covered: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Interested to know more about <u>The Business Research Company?</u>

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Or get a quick glimpse of our services here: https://www.youtube.com/channel/UC24 fl0rV8cR5DxlCpgmyFQ

Here is a list of reports from The Business Research Company similar to the Blood Cancer Drugs Global Market Report 2021:

Oncology Drugs Market - By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Cancer, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood Cancer), By Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/Drug Stores), By Route Of Administration (Oral, Parenteral), And By Region, Opportunities And Strategies – Global Forecast To 2030

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Cancer Biologics Global Market Report 2021 - By Type (Monoclonal Antibodies, Vaccines, Cell And Gene Therapy), By Application (Hospitals, Clinics), COVID-19 Growth And Change https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Artificial Intelligence Global Market Report 2021: COVID-19 Growth And Change To 2030 https://www.thebusinessresearchcompany.com/report/artificial-intelligence-market-global-report-2020-30-covid-19-growth-and-change

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293

The Business Research Company

Email: info@tbrc.info

Follow us on LinkedIn: https://bit.ly/3b7850r Follow us on Twitter: https://bit.ly/3b1rmjS Check out our Blog: https://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:

Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/549242708

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.